-The Hindu Business Line Frowns on India’s IP laws; New Delhi unfazed, says laws are TRIPS-compliant New Delhi: Expressing its disappointment with India for not making adequate changes in its IP laws and regulations despite announcing its National IPR policy last year, the US Trade Representative’s (USTR) office has once again placed the country in the ‘priority watch’ list in this year’s edition of the Special 301 report. “Almost a year after the...

-The Hindu Growing disenchantment with the existing model of globalisation is also a historic opportunity to frame new rules granting equal opportunities to all in the global marketplace The visit of Roberto Azevêdo, Director General of the World Trade Organisation (WTO) to India, from February 8, comes at a juncture when the framework of global trade rules is undergoing a shake-up. The Trans-Pacific Partnership (TPP) — which had almost become the standard...

-The Hindu Only science can ensure commercial viability and protection of indigenous breeds. With the Tamil Nadu Governor clearing an ordinance on jallikattu, the question is whether the sport will help preserve indigenous breeds of cattle. The proponents of jallikattu say that first, if the sport is banned, owners of indigenous bulls may no longer find it worth preserving the indigenous variants. Second, they say it is the ‘untamed’ bull that is...

-Down to Earth A high level UN panel on Access to Medicines wants members to make full use of TRIPS flexibilities to protect public health If ever India needed a clear endorsement of its laws on Intellectual Property Rights (IPRs) and their application in meeting public health priorities, it has come from the highest quarters. The report of the UN Secretary General’s High Level Panel (HLP) on Access to Medicines has, directly...

-The Hindu The proposal to extend the time limit for State-level drug regulatory approvals from four to 10 years could hit the generics market In a scathing letter to the Government of India, the Indian Pharmaceutical Alliance (IPA) took issue with what it considered to be a backdoor extension for data exclusivity norms in the country. It pointed to the recent government proposal to change the four-year time limit for State-level drug...